Excited to share our latest findings on the complex challenges of diagnosing PID in the context of SID linked to B-cell malignancies. Stay tuned for insights!
https://t.co/Y6I8HaoANq
Fantastic talks by Dr. Jacques Rivière and Dr. Eleonora Gambineri about how truncate time to immunodeficiency diagnosis at #ESID2024#Grifols symposium today
Engineered T cells (CAR T) is a transformative Rx for cancer and emerging for autoimmune diseases.
A meta-analysis of >7,600 patients in 18 clinical trials and 28 real-world studies highlights the risk of infection during follow-up as the principal cause of non-relapse mortality
https://t.co/7skI72wtY3
@NatureMedicine@KRejeski@DavidCdSMD@MSKCancerCenter
🌍 Our first day at the Global Stakeholders Summit is actively unfolding with vibrant discussions, exploring new horizons and innovations for global progress in PIDs!
#GlobalStakeholdersSummit#PIDs#Innovation
Economic Impact of Immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer. A single center observational study
https://t.co/i7SAaU88fQ
Patients with immunodeficiency are often undiagnosed or experience marked delay in detection.
#AI to the rescue.
https://t.co/OVkDQGz1Id @ScienceTM@ManishButte@UCLA
Congratulations to Dr. Charlotte Cunningham-Rundles, recipient of the 2024 Joachim Hilfenhaus Award. She receives this honor for her exceptional contributions to the field of immunology. Learn more about her impressive work at @IcahnMountSinai: https://t.co/C4eET0f60Z #IPPC2024
How can artificial intellingence help detect patients at risk of primary immunodeficiency? Dr. Nick Rider @NRider70 explained it to us at #IPIC2023#IPICmoment . Excellent talk!